Overview
Tetrabenazine is a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with tetrabenazine, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs
Or
Authorizations may be granted when both of the following criteria are met:
1. Member has a diagnosis of chorea associated with Huntington disease
2. The prescriber is a neurologist or in consultation with a neurologist

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s improvement in overall disease activity

Limitations
1. Initial approvals will be for 12 months
2. Reauthorizations will be for 36 months
3. The following quantity limits apply:

<table>
<thead>
<tr>
<th>Tetrabenazine</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.5mg</td>
<td>120 tablets per 30 days</td>
</tr>
<tr>
<td>25mg</td>
<td>60 tablets per 30 days</td>
</tr>
<tr>
<td></td>
<td>Maximum total daily dose is 100 mg</td>
</tr>
</tbody>
</table>
Appendix

Recommended Dosing

- **Initiation**: 12.5 mg per day given once in the morning.
- **Titration**: After 1 week, dose can be increased to 25 mg per day given as 12.5 mg twice a day. Continue to titrate slowly at weekly intervals of 12.5 mg, to allow identification of the dose that reduces chorea and is well tolerated.
- **Maximum single dose**: is generally recommended to be 25 mg, including poor CYP2D6 metabolizers; however, a max single dose of 37.5 mg is recommended in extensive and intermediate CYP2D6 metabolizers.
- **Maximum daily dose**: Total daily dose is 100 mg. In CYP2D6 poor metabolizers, maximum daily dose of 50 mg is recommended. In intermediate and extensive CYP2D6 metabolizers, a maximum daily dose of 100 mg is also recommended.

References

1. Xenazine (tetrabenazine) tablets [prescribing information]. Deerfield, IL: Lundbeck; September 2018

Review History

06/15/09 - Reviewed
08/03/09 - Implemented
06/21/10 - Reviewed
06/27/11 - Updated
06/25/12 - Reviewed
06/24/13 - Reviewed
06/23/14 - Reviewed
06/22/15 - Reviewed
06/27/16 - Reviewed
09/18/17 - Reviewed
04/17/19 – Reviewed
05/20/2020 – Reviewed and Updated May P&T Mtg; removed black box warning from criteria; references updated; added QL to criteria; added started and stabilized statement. Effective 8/1/20.

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.